Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2

DNA and Cell Biology

Volumn 34, Issue 1, 2015, Pages 69-77

  Xu, Sanxiong ^a,b   Yang, Zuozhang ^a   Zhang, Jinyu ^a   Jiang, Yongxin ^a   Chen, Yongbin ^c   Li, Hongjun ^d   Liu, Xuefeng ^a   Xu, Da ^a   Chen, Yanjin ^a   Yang, Yihao ^a   Zhang, Ya ^a   Li, Dongxu ^a   Xia, Junfeng ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b Department of Orthopedics First People's Hospital of Dali   (China)

^c KUNMING INSTITUTE OF ZOOLOGY   (China)

^d INSTITUTE OF MEDICAL BIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BETA CATENIN; HEPARANASE; HEPARANASE 1; LYMPHOID ENHANCER FACTOR 1; NRAS PROTEIN; PROTEIN; UNCLASSIFIED DRUG; BETA GLUCURONIDASE; BRAF PROTEIN, HUMAN; CTNNB1 PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; LEF1 PROTEIN, HUMAN; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN;

ACRAL MELANOMA; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CODON; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PIGMENTED NEVUS; PROTEIN EXPRESSION; STAINING; TUMOR INVASION; WESTERN BLOTTING; DNA MUTATIONAL ANALYSIS; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK; SKIN TUMOR; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GLUCURONIDASE; GTP PHOSPHOHYDROLASES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOID ENHANCER-BINDING FACTOR 1; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS B-RAF; RISK; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84920446894     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2014.2590     Document Type: Article

References (43)

1. Adhami, V.M., Siddiqui, I.A., Ahmad, N., Gupta, S., and Mukhtar, H. (2004). Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res 64, 8715-8722.
2. Alexiades-Armenakas, M.R. (2012). Melanoma-detecting technologies and standard of care. J Drugs Dermatol 11, 1270-1271.
3. Aviles-Izquierdo, J.A., Longo-Imedio, M.I., and Lazaro-Ochaita, P. (2010). Acral cutaneous melanoma in a Spanish Caucasian population. Melanoma Res [Epub ahead of print]; DOI: 10.1097/CMR.0b013e3282f1d2b6
4. Bradford, P.T., Goldstein, A.M., McMaster, M.L., and Tucker, M.A. (2009). Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005. Arch Dermatol 145, 427-434.
5. Chen, Y., Huang, L., and Yu, J. (2012). Evaluation of heparanase and matrix metalloproteinase-9 in patients with cutaneous malignant melanoma. J Dermatol 39, 339-343.
6. Damsky, W.E., Curley, D.P., Santhanakrishnan, M., Rosenbaum, L.E., Platt, J.T., Gould Rothberg, B.E., et al. (2011). betacatenin signaling controls metastasis in Braf-activated Ptendeficient melanomas. Cancer Cell 20, 741-754.
7. Day, C.P., and Merlino, G. (2011). Illuminating progression: tracking melanoma metastasis in a gene therapy setting. Pigment Cell Melanoma Res 24, 260-261.
8. Eichhoff, O.M., Weeraratna, A., Zipser, M.C., Denat, L., Widmer, D.S., Xu, M., et al. (2011). Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching. Pigment Cell Melanoma Res 24, 631-642.
9. Endo, K., Maejara, U., Baba, H., Tokunaga, E., Koga, T., Ikeda, Y., et al. (2001). Heparanase gene expression and metastatic potential in human gastric cancer. Anticancer Res 21, 3365-3369.
10. Espada, J., Calvo, M.B., Diaz-Prado, S., and Medina, V. (2009). Wnt signalling and cancer stem cells. Clin Transl Oncol 11, 411-427.
11. Fernandez-Flores, A. (2012). Prognostic factors for melanoma progression and metastasis: from hematoxylin-eosin to genetics. Rom J Morphol Embryol 53, 449-459.
12. Friedlander, P., Hodi, F.S. (2010). Advances in targeted therapy for melanoma. Clin Adv Hematol Oncol 8, 619-627.
13. Garber, K. (2009). Cancer research. Melanoma drug vindicates targeted approach. Science 326, 1619.
14. Gartner, J., Davis, S., Wei, X., Lin, J.C., Teer, J.K., Rosenberg, S.A., et al. (2012). Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma. BMC Genomics 13, 505.
15. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363, 711-723.
16. Jemal, A., Siegel, R., Xu, J., and Ward, E. (2010). Cancer statistics, 2010. CA Cancer J Clin 60, 277-300.
17. Klit, A., Drejoe, J.B., and Drzewiecki, K.T. (2011). Trends in the incidence of malignant melanoma in Denmark 1978-2007. Incidence on the island of Bornholm compared with the whole country incidence in Denmark. Dan Med Bull 58, A4229.
18. Lewis, K.D., Robinson, W.A., Millward, M.J., Powell, A., Price, T.J., Thomson, D.B., et al. (2008). A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs 26, 89-94.
19. Liu, X., Fang, H., Chen, H., Jiang, X., Fang, D., Wang, Y., et al. (2012). An artificial miRNA against HPSE suppresses melanoma invasion properties, correlating with a down-regulation of chemokines and MAPK phosphorylation. PLoS One 7, e38659.
20. Liu, X.Y., Fang, H., Yang, Z.G., Wang, X.Y., Ruan, L.M., Fang, D.R., et al. (2008). Matrine inhibits invasiveness and metastasis of human malignant melanoma cell line A375 in vitro. Int J Dermatol 47, 448-456.
21. Ma, M.W., Qian, M., Lackaye, D.J., Berman, R.S., Shapiro, R.L., Pavlick, A.C., et al. (2012). Challenging the current paradigm of melanoma progression: brain metastasis as isolated first visceral site. Neuro Oncol 14, 849-858.
22. Maelandsmo, G.M., Holm, R., Nesland, J.M., Fodstad, O., and Florenes, V.A. (2003). Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma. Clin Cancer Res 9, 3383-3388.
23. Mitra, D., Luo, X., Morgan, A., Wang, J., Hoang, M.P., Lo, J., et al. (2012). An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature 491, 449-453.
24. Mueller, D.W., and Bosserhoff, A.K. (2009). Role of miRNAs in the progression of malignant melanoma. Br J Cancer 101, 551-556.
25. Murakami, T., Toda, S., Fujimoto, M., Ohtsuki, M., Byers, H.R., Etoh, T., et al. (2001). Constitutive activation of Wnt/beta-catenin signaling pathway in migration-active melanoma cells: role of LEF-1 in melanoma with increased metastatic potential. Biochem Biophys Res Commun 288, 8-15.
26. Nelson, W.J., and Nusse, R. (2004). Convergence of Wnt, betacatenin, and cadherin pathways. Science 303, 1483-1487.
27. Orgaz, J.L., and Sanz-Moreno, V. (2013). Emerging molecular targets in melanoma invasion and metastasis. Pigment Cell Melanoma Res 26, 39-57.
28. Pacheco, I., Buzea, C., and Tron, V. (2011). Towards new therapeutic approaches for malignant melanoma. Expert Rev Mol Med 13, e33.
29. Purdue, M.P., Freeman, L.E., Anderson, W.F., and Tucker, M.A. (2008). Recent trends in incidence of cutaneous melanoma among US Caucasian young adults. J Invest Dermatol 128, 2905-2908.
30. Reed, K.B., Brewer, J.D., Lohse, C.M., Bringe, K.E., Pruitt, C.N., and Gibson, L.E. (2012). Increasing incidence of melanoma among young adults: an epidemiological study in Olmsted County, Minnesota. Mayo Clin Proc 87, 328-334.
31. Reya, T., and Clevers, H. (2005). Wnt signalling in stem cells and cancer. Nature 434, 843-850.
32. Ricotti, C., Bouzari, N., Agadi, A., and Cockerell, C.J. (2009). Malignant skin neoplasms. Med Clin North Am 93, 1241-1264.
33. Rivera, R.S., Nagatsuka, H., Siar, C.H., Gunduz, M., Tsujigiwa, H., Han, P.P., et al. (2008). Heparanase and vascular endothelial growth factor expression in the progression of oral mucosal melanoma. Oncol Rep 19, 657-661.
34. Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E., and Polakis, P. (1997). Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275, 1790-1792.
35. Saleem, M., Maddodi, N., Abu Zaid, M., Khan, N., bin Hafeez, B., Asim, M., et al. (2008). Lupeol inhibits growth of highly aggressive human metastatic melanoma cells in vitro and in vivo by inducing apoptosis. Clin Cancer Res 14, 2119-2127.
36. Smyth, E.C., Flavin, M., Pulitzer, M.P., Gardner, G.J., Costantino, P.D., Chi, D.S., et al. (2011). Treatment of locally recurrent mucosal melanoma with topical imiquimod. J Clin Oncol 29, e809-e811.
37. Takahashi, Y., Nishikawa, M., Suehara, T., Takiguchi, N., and Takakura, Y. (2008). Gene silencing of beta-catenin in melanoma cells retards their growth but promotes the formation of pulmonary metastasis in mice. Int J Cancer 123, 2315-2320.
38. Takaoka, M., Naomoto, Y., Ohkawa, T., Uetsuka, H., Shirakawa, Y., Uno, F., et al. (2003). Heparanase expression correlates with invasion and poor prognosis in gastric cancers. Lab Invest 83, 613-622.
39. Turajlic, S., Furney, S.J., Lambros, M.B., Mitsopoulos, C., Kozarewa, I., Geyer, F.C., et al. (2012). Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res 22, 196-207.
40. Wagner, M., Suarez, E.R., Theodoro, T.R., Machado Filho, C.D., Gama, M.F., Tardivo, J.P., et al. (2012). Methylene blue photodynamic therapy in malignant melanoma decreases expression of proliferating cell nuclear antigen and heparanases. Clin Exp Dermatol 37, 527-533.
41. Widlund, H.R., Horstmann, M.A., Price, E.R., Cui, J., Lessnick, S.L., Wu, M., et al. (2002). Beta-catenin-induced melanoma growth requires the downstream target Microphthalmia associated transcription factor. J Cell Biol 158, 1079-1087.
42. Wolf, A.M., Wender, R.C., Etzioni, R.B., Thompson, I.M., D'Amico, A.V., Volk, R.J., et al. (2010). American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 60, 70-98.
43. Yingying, X., Yong, Z., Zhenning, W., Xue, Z., Li, J., Yang, L., et al. (2009). Role of heparanase-1 in gastric carcinoma invasion. Asian Pac J Cancer Prev 10, 151-154.